- Home
- NPCE vs ADCT Comparison
NPCE vs ADCT Comparison
Compare NPCE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | ADCT |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.6M | 484.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NPCE | ADCT |
|---|---|---|
| Price | $14.54 | $4.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $18.33 | $7.50 |
| AVG Volume (30 Days) | 206.8K | ★ 936.4K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,986,000.00 | $81,357,000.00 |
| Revenue This Year | $0.93 | $1.15 |
| Revenue Next Year | $25.47 | $86.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | 14.85 |
| 52 Week Low | $7.56 | $1.05 |
| 52 Week High | $18.97 | $4.98 |
Technical Indicators
Market Signals| Indicator | NPCE | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 49.70 |
| Support Level | $12.47 | $3.79 |
| Resistance Level | $16.96 | $4.63 |
| Average True Range (ATR) | 0.82 | 0.30 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 60.13 | 22.12 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).